20.01.2023 • News

Solvay Launches Bio-silica, Plans Capacity in Italy, USA

Solvay is investing an undisclosed sum at its site in Livorno, Italy, to launch its first circular highly dispersible silica (HDS), which is made with bio-based sodium silicate derived from rice husk ash.

In addition, it plans to build a new HDS plant in North America in the coming years and is investigating projects in Asia and South America.

According to the Belgian chemicals company, its “breakthrough” silica process, coupled with renewable energy integration at Livorno, will reduce CO2 at the plant by 50% per ton of silica. This, said Solvay, will make Livorno Europe’s best-in-class silica production site in terms of CO2 footprint. Production is expected to start by the end of 2024.

The circular HDS will gradually replace Solvay’s existing Zeosil range, which is used to make energy-efficient tires, as well as to reinforce various rubber goods, including those used in home & personal care and the feed & food industries.

In separate news, Solvay is relocating its headquarters from Neder-over-Heembeek to the Brussels municipality of Haren. The move of all administrative and research teams will be done in phases during a 12-month period starting in April this year.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Solvay

Rue du Prince Albert 33
1050 Bruxelles
Belgium

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read